Form 8-K - Current report:
SEC Accession No. 0001193125-24-194427
Filing Date
2024-08-06
Accepted
2024-08-06 07:33:30
Documents
15
Period of Report
2024-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d878101d8k.htm   iXBRL 8-K 25892
2 EX-99.1 d878101dex991.htm EX-99.1 119628
6 GRAPHIC g878101g0806050139404.jpg GRAPHIC 3772
  Complete submission text file 0001193125-24-194427.txt   292583

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20240806.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20240806_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20240806_pre.xml EX-101.PRE 11258
17 EXTRACTED XBRL INSTANCE DOCUMENT d878101d8k_htm.xml XML 3628
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 241177117
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)